-methylguanine-DNA methyltransferase (MGMT), a ubiquitous DNA repair protein, removes the mutagenic DNA adduct O 6 -alkylguanine, which is synthesized both endogenously and after exposure to alkylnitrosamines and alkylating antitumor drugs such as 2-chloroethyl-Nnitrosourea (CNU). The MGMT gene is highly regulated in mammalian cells and its overexpression, observed in many types of tumor cells, is often associated with cellular resistance to CNU. Dexamethasone, a synthetic glucocorticoid hormone, was found to increase MGMT expression in HeLa S3 cells, concomitant with their increased resistance to CNU. Two putative glucocorticoid responsive elements (GREs) were identi®ed in the human MGMT (hMGMT) promoter. Transient expression of the luciferase reporter gene driven by an hMGMT promoter fragment containing these GREs was activated by dexamethasone. DNase I footprinting assays demonstrated the binding of glucocorticoid receptor to these sequences. In vitro transcription experiment showed that these DNA sequences are functional in glucocorticoid receptor signal-mediated activation of transcription. These results suggest glucocorticoid-mediated induction of the MGMT gene contributes to high level expression of MGMT.
Introduction
-methylguanine-DNA methyltransferase (MGMT), a ubiquitous DNA repair protein, is responsible for removal of O 6 -alkylguanine from DNA. This alkylated base adduct is generated in DNA either endogenously or after exposure to alkylating carcinogens and antitumor drugs, such as chemotherapeutic 2-chloroethyl-N-nitrosourea (CNU) derivatives (Mitra and Kaina, 1993; Pegg, 1990; Singer and Gruenberger, 1983) . Although O 6 -methylguanine is a relatively minor component of methylated base adducts, it is believed to be the major mutagenic and carcinogenic lesion because its pairing with thymine, in addition to cytidine, during DNA replication, leading to a GC to AT transition mutation (Eadie et al., 1984; Snow et al., 1984) . Moreover, the CNU derivatives yield O 6 -chloroethylguanine in DNA which ultimately lead to the formation of stable cytotoxic DNA crosslinks (Erickson et al., 1980; Ludlum, 1990) . Repair of O 6 -alkylguanine adducts by MGMT is thus eective in protecting cells against the mutagenic, carcinogenic and cytotoxic eects of DNA alkylating agents (Brent et al., 1985; Robins et al., 1983; Schold et al., 1989) .
Most normal cells and the majority of human tumor cells express the MGMT gene, although the level of expression varies widely in a tissue-and cell-typespeci®c manner (D'ambrosio et al., 1987; Sagher et al., 1989; Washington et al., 1989) . A few untransformed rodent cells and a fraction of primary human tumor cells (710%) express very low levels (Day et al., 1980; Mitra and Kaina, 1993; Myrnes et al., 1984; Pegg, 1990; Pieper et al., 1991; Yarosh et al., 1983) ; these MGMT-de®cient (Mex 7 ) cell lines are very sensitive to N-nitrosomethyl-N-nitrosoureatype alkylating carcinogens and drugs. Conversely, some tumor cells express MGMT at a high level and this has profound clinical implications, because MGMT appears to be the only protein involved in removal of the O 6 -chloroethylguanine, which is the direct consequence of treatment with CNU derivatives. Thus, resistance to CNU derivatives often correlates with tumor MGMT levels (Brent et al., 1985; Kokkinakis et al., 1997; Pegg, 1990) . This is also consistent with the observation that inactivation of MGMT by treatment with O 6 -benzylguanine significantly increases sensitivity of tumor cells to CNU derivatives (Liu et al., 1996; Pegg et al., 1995) . Thus elucidation of the molecular mechanisms controlling MGMT expression may lead to development of drugs that speci®cally inhibit or enhance MGMT expression, and is of signi®cant clinical importance. Earlier studies showed that MGMT expression can be enhanced by a variety of genotoxic agents in rodent and human cell lines (Fritz et al., 1991) and more recently studies have implicated altered chromatin organization and nucleosome positioning and aberrant silencing in the CpG island in the promoter region in regulating the expression of the gene (Patel et al., 1997; Watts et al., 1997) . However, the cis-elements present in the promoter or the transacting factors responsible for the variable, cell-speci®c expression of MGMT are not known.
The hMGMT gene, encoding an mRNA of 950 nucleotides, consists of 5 exons and spans more than 170 kilobase pair (kb; Nakatsu et al., 1993) , and its 5'-regulatory promoter has been cloned and characterized for known regulatory sites (Harris et al., 1991) . The DNA sequence in the 5' region preceding exon 1 is extremely GC-rich and lacks TATA as well as CAAT boxes. The presence of two non-consensus glucocorticoid response elements (GREs) separated by 20 base pairs (bp) and located 1 kb upstream of the transcription start site, suggested potential regulation of MGMT expression by glucocorticoids. Two AP-1 sites were also found in close proximity. Based on cis-sequences identi®ed in many glucocorticoid-responsive genes, a GRE consensus sequence of 15 nucleotides was deduced; it contains two hexameric, partially palindromic half-sites, GGTACA and TGT T / C CT, separated by three nonspeci®c nucleotides. The candidate GREs in the hMGMT promoter have conserved the stronger, TGTCCT half-sites but are divergent from the consensus GRE in the other half site.
Glucocorticoids exert a multitude of physiological eects by modulating the expression of speci®c genes, mostly at the transcriptional level by binding to and activating intracellular glucocorticoid receptors (GR; Beato, 1989; McEwan et al., 1995; Tsai and O'Malley, 1994) . The steroid-receptor complexes may interact with the GREs of glucocorticoid-responsive genes and/ or with other transcription factors, e.g. AP-1 (Diamond et al., 1990; Saatcioglu et al., 1994) . In addition to their use as anti-in¯ammatory agents, glucocorticoids are often used to reduce peritumoral edema, one of the commonest causes of neurologic deterioration, in brain tumor patients undergoing chemotherapy (Levin et al., 1997; Heiss et al., 1996; Yung, 1990) . Modulation of DNA repair activity, in this case an increase, by these steroids may reduce the therapeutic eciency of CNU-type alkylating drugs often used in therapy of CNS tumors. It is thus important to test whether glucocorticoids can induce MGMT in tumor cells. We have analysed the hMGMT regulatory domain and ®nd that the hMGMT gene is induced by glucocorticoid mediated by the GREs.
Results

Dexamethasone-mediated activation of the hMGMT gene
We have characterized in HeLa S3 cells the role of glucocorticoid in h-MGMT mRNA expression, protein formation and bioactivity. HeLa S3 cells were stimulated with 0.01 mM dexamethasone for 0 to 24 h and MGMT mRNA expression was analysed ( Figure  1 ). Levels of MGMT mRNA started to increase at 12 h and continued to rise to a maximum up to 17 ± 18 h, after which they remained steady until 24 h. Quantitation of MGMT mRNA: 18S rRNA ratios showed a maximal 2.5-fold increase. Simultaneous Western analysis of protein extracts from the same cell samples for induced MGMT protein synthesis demonstrated a twofold increase at 15 h after which the induced level was maintained for at least 24 h (Figure 2 ). Because glucocorticoid-dependent activation of genes requires expression of glucocorticoid receptor, we measured the level of GR in HeLa S3 cells by ligand binding assay. Approximately 15 ± 18,000 GR molecules/cell were present in log-phase HeLa culture. Correlation of MGMT activity with CNU resistance An increase in hMGMT protein level might be expected to lead to a corresponding increase in hMGMT function. It is known that increased hMGMT activity can lead to resistance to alkylating agents. To con®rm this in dexamethasone-treated HeLa S3 cells, we evaluated whether the elevated hMGMT protein level was correlated with resistance against such alkylating agents as BCNU in vivo. HeLa S3 cells were treated with dexamethasone (0.01, 0.05 or 0.1 mM) for 16 h before treatment with diering concentrations of BCNU for 1 h in a serum-free medium. Cells were then grown in fresh medium for 9 ± 12 days, and survival was tested by clonogenic assay. The dexamethasone treatment led to a signi®cantly increased survival to challenge by BCNU. At 40 mM, BCNU killed almost all of control HeLa S3 cells, but 10% of the dexamethasone treated cells showed resistance ( Figure 3 ). This corresponds to a *2 log increase in the number of clonogenic cells.
Deletion analysis for identi®cation of GRE in hMGMT promoter
We evaluated whether the glucocorticoid response elements in the promoter of the hMGMT gene might be responsible for dexamethasone-mediated mRNA induction and protein synthesis. To test the transcriptional regulatory elements we constructed recombinant plasmids in which a luciferase reporter gene was placed under the control of various lengths of 5'¯anking region of the hMGMT promoter and tested the luciferase activity in transient expression assays (Figure 4) . Transfection experiments showed that pML772/+24 was able to produce basal transcription in HeLa S3 cells; the larger promoter fragments showed a stepwise increase in level of expression (data not shown). Figure 4 shows the induction in expression of luciferase activity in extracts from HeLa S3 cells transfected with the above constructs and stimulated with dexamethasone. A nearly fourfold increase in luciferase activity was observed with the construct p7954/+24ML. When the regulatory region was shortened at the 5' terminus by 88 nucleotides (p7866/+24ML), induction was reduced to twofold. Interestingly, the p72500/+24ML and longer reporter constructs also showed only a 2±3-fold induction, suggesting the presence of negative upstream regulatory element(s). The level of induction from the p7954/+24ML was about 2.5-fold above that from p772/+24ML, a fold of induction comparable to that of endogenous hMGMT mRNA or protein. A computer assisted search for sequences in the hMGMT promoter similar to the previously described consensus GRE revealed two putative half-site GREs, at positions 7929 to 7914 and 7892 to 7877. To analyse the regulatory property of these sequences, we Figure 3 Dexamethasone-mediated protection of HeLa S3 cells from BCNU toxicity. Survival was measured by clonogenic assay. Open circle, ®lled circle, ®lled triangle and ®lled square *, *,ã nd & represent 0 (control), 10 nM, 50 nM and 100 nM dexamethasone treated cells, respectively. Percent survival was expressed as the mean+s.e. of three independent experiments Figure 4 Dexamethasone-mediated induction of luciferase activity expressed from a hMGMT promoter. Schematic representation of DNA constructs containing various lengths of hMGMT promoter linked to the luciferase gene (pGL2 basic) as described in Materials and methods, along with their speci®c induction by dexamethasone in transiently transfected HeLa S3 cells. Fold of induction was calculated as the ratio of the luciferase activities from induced (dexamethasone treated) vs control (ethanol treated) cells and was expressed as mean+s.e. of three to six independent experiments. Numbers in plasmids names refer to the position of the ®rst and the last nucleotides of the hMGMT gene relative to the transcription start site (+1). The positions of restriction sites and of GRE-1 and GRE-2 are also indicated made deletion constructs by removing either GRE-1 or both GRE-1 and GRE-2. Deletion of GRE-1 had very little eect on induction, but deletion of both GREs caused a signi®cant reduction (compare p7954/ +24ML with p7900/+24ML and p7866/+24ML). However, glucocortidal induction was not completely abolished by deletion of the two GREs. The residual induction (about 1.5-fold) suggests that additional active cis-regulatory elements are present within the remaining region of hMGMT promoter, or that there are some GRE-like sequences present in the vector itself giving rise to the background inductive activity. To better de®ne the cis-acting sequences presumably mediating the eects of glucocorticoid on promoter activity, DNase I footprinting and in vitro functional analyses of the glucocorticoid receptor-binding sites were performed.
Footprinting of h-MGMT GREs with recombinant GR
A DNaseI protection assay on a 174 bp BamHI/ApaI fragment (7954 to 7780) containing both GRE-1 and GRE-2 was performed with the DNA-binding domain of hGR. As shown in Figure 5 , footprints were seen with both the GREs, 7929 to 7914 and 7892 to 7877 upstream of the transcriptional start site, arranged as imperfect palindromes separated by three nucleotides, typical of a functional GRE. As the concentration of GR-DNA binding domain was increased, GRE-2 was footprinted prior to GRE-1, and the protection patterns were also dierent.
GR-dependent activation of the hMGMT promoter in vitro
We tested the functionality of the putative MGMT GREs in an in vitro transcription assay. Tsai et al. (1990) have shown that pLov TATA, the parent plasmid used to generate pMGMT TATA gave only weak transactivation in the presence and absence of recombinant hGR, whereas there was strong increase in transcription with pPRE 2 TATA. In this assay, in addition to pMGMTTATA, we also used pPRE 2 TATA both for comparative purposes as well as to ensure the quality of the recombinant hGR preparation. pMGMTTATA, which contains two hexameric halfsites 20 bp apart, showed a fourfold stimulation (Figure 6a , lanes 3 and 4) when hGR was added, while pPRE 2 TATA, which contain two copies of the palindromic GRE from the tyrosine aminotransferase (TAT) gene showed a tenfold stimulation (Figure 6a , lanes 1 and 2) upon addition of an identical of ®ve to six independent experiments. The symbols of wild-type and mutated plasmids are described in Materials and methods quantity of hGR. The contribution of GRE-1 and GRE-2 to transcription of the reporter cassette was further analysed in detail (Figure 6c ) by comparing the amount of hGR-dependent transcription from plasmids containing mutations in either GRE-1 (MW) or GRE-2 (WM) or both (MM). The results show that both GRE's contribute to GR-dependent activation. Relative to some threefold induction due to 372 bp hMGMT promoter fragment, the 62 bp fragment with WW, MW, WM and MM showed induction of 2.4-, 1.6-, 1.8-and 1.4-fold, respectively. Although the response was modest, our results were reproducible in multiple independent experiments. Discussion DNA repair activity in bacteria is often inducible in response to speci®c DNA damage (Friedberg et al., 1995) . Although nonspeci®c induction of DNA repair genes has been observed in mammalian cells after exposure to a variety of genotoxic agents, the eect is often small and limited to very few cell lines. Our ®nding that a hormonally active steroid activates expression of a DNA repair gene, namely, MGMT, raises the question of how DNA repair in general is modulated in mammalian cells.
We made parallel determination of the levels of hMGMT mRNA and protein as well as its activity in HeLa S3 cells treated with dexamethasone. As we have examined, HeLa S3 expresses a high level of GR. Therefore, dexamethasone-dependent activation of hMGMT gene should not be restricted by the level of GR. We found a 2 ± 3-fold induction of both mRNA and protein levels at 15 h and beyond. As expected, the induction by dexamethasone was associated with signi®cantly increased resistance of HeLa S3 cells to BCNU, a CNU derivative. Dexamethasone-dependent induction was also observed in MIA PaCa-2, a human pancreatic carcinoma cell line, and in IMR-90, a human diploid lung ®broblast and its transformed lines. Results similar to ours were recently reported in studies with rat hepatoma cell line by Grombacher et al. (1996) , who found a ®vefold increase in MGMT mRNA level after dexamethasone treatment and a similar induction in transient expression of a reporter gene under control of the hMGMT promoter. However, in that report no systematic analysis of the putative GRE(s) in MGMT promoters was performed. We here have identi®ed and characterized the DNA sequences that confer the bulk of the glucocorticoid responsiveness to the hMGMT gene. The functional GREs we have identi®ed are located about 929 bp upstream of the transcription start site. The functionality of these GREs was established by several independent criteria, namely, glucocorticoid-dependent induction of the luciferase reporter gene, DNase I footprinting assay, and in vitro transcription assays. DNase I footprinting assays con®rmed the binding of the DNA binding domain of hGR to the putative sequences responsible for dexamethasone induction. GRE-2 seemed to show a stronger binding to GR than did GRE-1, and may be more important in the induction; however, further analysis will be needed to better de®ne the individual roles of these two elements. The GREs were also found functional, though with a reduced eciency compared to palindromic GRE, when placed upstream of a TATA-based promoter, as shown by hGR-dependent increase in transactivation from pMGMT TATA. Detailed analysis of wildtype and mutant MGMT GREs also con®rmed a signi®cant dierence in functionality between the wildtype and mutant plasmids. Both GRE's appear to be involved in GR-dependent activation because mutation of either one signi®cantly reduced the activation level. These studies strongly suggest that increased transcription signi®cantly contributes to the overall increase in hMGMT mRNA level. It is interesting to note that, unlike most genes responsive of GRE-mediated regulation, the MGMT gene does not contain a TATA element. However, the function of its GREs is independent of the presence of this element. The delayed induction of MGMT by dexamethasone may re¯ect the requirement for synthesis of secondary mediator protein(s) involved in the hormonal induction, or that a longer time is needed before the increased synthesis reaches a level sucient to be detected by the present methods.
The known cell type-speci®c variation in MGMT expression suggests that the MGMT promoter may be complex. We intend to identify the intermediates in the regulatory pathways in order to develop strategies for deliberate modulation of hMGMT gene expression, since it directly aects the biological outcome of exposure to many genotoxic alkylating agents and to antitumor drugs. The present study suggests that glucocorticoid-mediated activation of the MGMT gene may contribute to the overexpression of MGMT, often observed in tumor cells. Such a possibility could be directly tested and, if proven correct, will provide an opportunity for reversing MGMT overexpression by glucocorticoid antagonists. An important phenotype of some primary tumor cells is the near lack of expression of MGMT. These Mex 7 / Mer 7 cells are exquisitely sensitive to CNU-based drugs. The molecular basis for extinction of the MGMT gene is not known. It was recently suggested that altered chromatin organization and nucleosome positioning and aberrant silencing in the CpG island of the promoter region, surrounding of the MGMT gene is linked to Mex 7 phenotype (Patel et al., 1997; Watts et al., 1997) . However, the GRE sequences are located outside these CpG island regions and it appears that GREs in the MGMT promoter are involved in activation rather than repression. Finally, it should be stressed that downregulation of MGMT should result in increased therapeutic eciency of CNU-based drugs. By the same token, the common practice of administration of glucocorticoid together with CNU derivatives for treatment of certain cancers such as primary and metastatic brain tumors, multiple myeloma etc. needs to be reconsidered because hormone-mediated upregulation of MGMT may reduce the therapeutic eciency of the alkylating drug (Levin et al., 1997; Salmon and Cassady, 1997) .
Material and methods
Cell lines and reagents
The HeLa S3 (ATCC CCL 2.2) cell line was used in all experiments. Fetal bovine serum, DMEM/F12 medium, Dulbecco's Phosphate buered saline and penicillinstreptomycin were purchased from Life Technologies. The kit for radio-labeling DNA probe was obtained from Pharmacia Biotech., Inc. The Enhanced Chemiluminescence (ECL) Western blotting kit was purchased from Amersham Corporation. N,N'-bis(2-chloroethyl)-N-nitrosourea (BCNU) was obtained from Bristol Laboratories. Dexamethasone and other reagents were of analytical grade and were obtained from Sigma.
Cell culture
HeLa S3 cells were grown in Dulbecco's modi®ed Eagle's Medium supplemented with F12 containing 5% (v/v) fetal bovine serum and 100 units/ml of penicillin/streptomycin. The cells were routinely grown in monolayer cultures at 378C in 5% CO 2 and had a doubling time of about 20 h. By subculturing when the cells reached approximately half con¯uence, growth was kept logarithmic. For transient transfection and other experiments, cells were plated 24 h before treatment so that they were at approximately 50% con¯uency at the time of use.
Northern blot analysis
Total cellular RNA was isolated from HeLa S3 cells using RNAzol (Tel-Test, Inc.) based on the method of Chomczynski and Saachi (1987) and quantitated spectrophotometrically. For Northern analysis, RNA was denatured by heating for 15 min at 658C in 0.56MOPS pH 7.8 buer containing 6.5% formaldehyde and 50% formamide and then fractionated by electrophoresis on 1% agarose gel containing 2.2M formaldehyde. The RNA was transferred onto a nylon membrane (Micron Separations, Incorporated) by capillary electrophoresis and then hybridized with 32 P-labeled probe for MGMT cDNA or 18S ribosomal RNA. The MGMT cDNA probe was an EcoRI fragment from pKT100 (Tano et al., 1990 ) and the 18S rRNA probe was a 1.15 kb BamHI ± EcoRI fragment from p5B (Bowman et al., 1981) . Both prehybridization and hybridization were carried out at 658C in 66SSC, 56Denhardt's, 0.1% SDS. The membranes were subsequently washed twice with 16SSC and 1% SDS for 30 min, and then with 0.16SSC and 1% SDS at 508C for required amount of time to reduce the background to an optimal level. The ®lters were exposed subsequently to either phosphor screen or Kodak-XAR ®lm at 7808C with intensifying screens for appropriate periods of time so that the signals were in the linear range. Signals were quanti®ed by using Imagequant (Molecular Dynamics) software or NIH Image (NIH) software, or both.
Western blot analysis
Immunoblotting analysis using polyclonal antibodies to hMGMT was performed on control or dexamethasonetreated HeLa S3 extracts. The monolayer cells were lysed by incubating with 400 ml/dish of lysis buer (50 mM Tris. HCl, pH 8, 150 mM NaCl, 0.1% SDS, 1% NP 40 and 50 mg/ml PMSF) on ice for 20 min. Cells were then scraped with a cell lifter, transferred to a microcentrifuge tube, vortexed for 5 s and centrifuged at 48C for 2 min at 15 000 g. Supernatants were transferred to a second tube, assayed for protein content (bicinchoninic acid procedure) and stored at 7808C. Samples (50 mg protein/lane) were electrophoresed in a SDS-polyacrylamide gel and then electrophoretically transferred to a nitrocellulose membrane (Protran TM , Schleicher & Schuell). The membranes were treated per manufacturer's instructions (ECL technique, Amersham). Polyclonal rabbit antisera against bacterially expressed human MGMT (Alpha Diagnostic International, SanAntonio, TX, USA) was used at 1 : 400 dilution. A hyper®lm (Amersham Corporation) was used to visualize the chemiluminescent bands. Exposure time was adjusted such that the signal intensity was in the linear range. Signals were quanti®ed as described in case of Northern Blot analysis.
Construction of plasmids
The 11.3 kb hMGMT genomic fragment isolated from an lEMBL clone was subcloned into pBluescript II SK+/7 phagemid at the SalI site. The construct was named pBS1202. After establishing a restriction map, various segments of the promoter region which included the transcription start site were subcloned in the pGL2 basic (Promega) vector (Figure 4) .
The 96 bp SmaI/XbaI fragment (containing the basal promoter region of hMGMT) was subcloned at the SmaI/ NheI site of pGL2 basic to generate luciferase expression plasmid p772/+24ML. The 599 bp PstI/XbaI fragment was ®rst cloned into pUC19 at the PstI/XbaI site. It was then cut out with EcoRV/XbaI and subcloned at the SmaI/NheI site of pGL2 basic to generate p7575/+24ML. The 978 bp BamHI/ XbaI fragment was ®rst subcloned into pUC19. The resultant recombinant was called p1911. The KpnI/XbaI fragment from p1911 was cloned into KpnI/NheI site of pGL2 basic to generate p7954/+24ML. The 2.5 kb SstI/XbaI and the 3.5 kb KpnI/XbaI fragments were subcloned in SstI/NheI and KpnI/NheI site of pGL2 basic respectively to generate p72500/+24 ML and p73500/+24 ML. The 9.5 kb SalI/ HindIII fragment was cloned in SmaI/HindIII site of pGL2 basic to generate p79500/+250 ML.
A KpnI site was generated by site-directed mutagenesis between GRE-1 and GRE-2 in p1911. The KpnI/XbaI digested 924 bp fragment lacking the GRE-1 was then subcloned into the KpnI/NheI site of pGL2 basic to generate p7900/+24ML. Similarly another KpnI site was generated 11 bp downstream of the GRE-2 in p1911 and KpnI/XbaI digested 890 bp fragment lacking both the GREs was subcloned into KpnI/NheI site of pGL2 basic to construct pML7866/+24ML. Site-directed mutagenesis was carried out using Stratagene's double-stranded site-directed mutagenesis kit. The kit is based on a modi®cation of the unique site elimination mutagenesis procedure described by Deng and Nickolo (1992) . The DNAs used for transfection were prepared by alkaline lysis procedure and then puri®ed on CsCl-ethidium bromide density gradients.
Assay for transiently expressed reporter gene
Transfection of HeLa S3 cells was carried out by electroporation (Izumi et al., 1996) because with this method the size of the vector does not signi®cantly aect the transfection eciency. About 1610 7 cells were trypsinized, washed twice and resuspended in 250 ml of ice cold Dulbecco's Phosphate buered saline. Luciferase expression plasmid (10 mg), along with b-galactosidase expression plasmid (5 mg) under the control of SV40 promoter (pSV b-gal; Promega), were mixed with the suspended cells in a 0.4 cm cuvette (BioRad), kept on ice for 10 min and transfected in a BioRad Gene Pulse electroporation unit at 960 mF capacitance and 250 V. After 30 min of incubation on ice, the cells were plated in normal media in 100 mm tissue culture dishes. Dexamethasone was added to the medium 5 ± 10 min after plating (the time giving maximal induction) and the cells were harvested 16 h after the shock. A preliminary time course study indicated that the level of expression is maximum at about 16 h and decreases signi®cantly at 48 h. Luciferase and b-galactosidase activity were measured using kits from Promega and the manufacturer-recommended protocols.
DNase I footprinting assay
The footprinting reaction was done essentially as described by Leblanc and Moss (1994) . The BamHI/XbaI hMGMT promoter fragment (subcloned in pUC19) was digested with BamHI and ApaI and a 175 bp fragment containing the sequences of both GRE-1 and GRE-2 was isolated. This fragment was labeled with a-32 P-dCTP (3000 Ci/mmol, DuPont-NEN) by ®lling in the 3' recessed BamHI end using FPLC pure DNA polymerase Klenow fragment (GIBCO ± BRL) and then puri®ed in a 5% non-denaturing PAG to remove unincorporated dNTPs. The binding reaction was performed in a total volume of 20 ml containing 10 ml of 26binding buer (20% glycerol, 2 mM EDTA, 4 mM MgCl 2 , 8 mM DTT, 100 mM NaCl and 40 mM HEPES, pH 7.9), 0.5 ml of 1 mg/ml poly[dI.dC], 2 ng of end-labeled DNA fragment (*10 000 c.p.m.) and varying amounts of bacterially expressed human GR DNA binding domain (GR-DBD, kindly provided by T Ma and EA Thompson). The reaction was incubated on ice for 20 min and then digested with 5 ml of 0.002 kU/ml DNase I (Sigma) for 2 min. The phenol chloroform-extracted and ethanol-precipitated DNA was electrophoresed in a 8% denaturing-polyacrylamide sequencing gel.
In vitro transcription
Transcriptional run-on synthesis was performed to test the transcriptional activation function of hMGMT GRE in heterologous promoter context. MGMT-GRE G-free cassette reporter plasmid pMGMTTATA (generated by inserting the 372 bp BamHI ± PstI fragment containing putative MGMT GRE elements 1 and 2 into the BglII site of pLov TATA ; in the forward orientation) was used to test the function of MGMT GREs. For further characterization of the GRE-1 and GRE-2, 62-mer oligonucleotides containing mutation(s) in none, either one or both were designed and cloned in BglII site of pLovTATA in the forward orientation. The plasmid names include WW, WM, MW and MM to indicate wildtype, mutation in GRE-2, mutation in GRE-1 and mutations in both, respectively. The second half-site TGT of the GREs were changed to AAA in all of the mutant constructs. pLovTATA, containing only the ovalbumin TATA box, was used as a negative control and pPRE 2 TATA , which contains two copies of the palindromic GRE from the tyrosine aminotransferase gene, was used for comparison of strength. pAdML200 was added to each tube as an internal control. The in vitro transcription reaction was performed essentially as described by Tsai et al. (1990) using HeLa S3 nuclear extract (Shapiro et al., 1988) supplemented with human glucocorticoid receptor (hGR, 100 ng/30 ml reaction volume). pAdML200 (10 ng) along with 250 ng of pLovTATA, pMGMTTATA or pPRE 2 TATA were used in the reaction. This assay method generates one correctly initiated transcript and one non-speci®c read-through transcript (of a slightly larger size) for each template (Bagchi et al., 1990; Klein-Hitpass et al., 1990) .
